Lexeo reports Q2 net loss $26.1M, advances LX2006 with Breakthrough Therapy, appoints new CFO

Lexeo Therapeutics, Inc.

2025-Q2 EPS reported -$1.53

Net loss $26.1M ($0.60/sh) vs $21.2M ($0.64/sh) in Q2 2024; cash $152.5M expected to fund operations into 2028.
LX2006 granted FDA Breakthrough Therapy designation based on interim data; registrational study expected early 2026.
Eight participants dosed in Phase I/II HEROIC-PKP2 trial of LX2020; interim data update expected H2 2025.
Closed $80M equity financing in May 2025; strategic partnership for non-viral RNA cardiac therapies.
Louis Tamayo appointed CFO effective Aug 15, 2025, succeeding Kyle Rasbach.

item 2.02item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.